Less Ads, More Data, More Tools Register for FREE

Pin to quick picksSmith & Nephew Regulatory News (SN.)

Share Price Information for Smith & Nephew (SN.)

Share Price is delayed by 15 minutes
Get Live Data
1,139.00    0.00 (0.00%)
Bid:
1,060.00
Ask:
0.00
Spread: 81.50 (7.689%)
Market Cap: £9.67b
SN. Live PriceLast checked at - London Stock Exchange

Intraday Smith & Nephew Share Chart

Pre Stabilisation Notice

27 May 2026 09:31

RNS Number : 8736F
HSBC Bank plc
27 May 2026
 

27th May 2026

 

Smith & Nephew plc

Pre Stabilisation Notice

HSBC (contact: syndexecution@noexternalmail.hsbc.com) hereby gives notice, as Stabilisation Coordinator, that the Stabilisation Manager(s) named below may stabilise the offer of the following securities

The securities:

Issuer:

Smith & Nephew plc

Guarantor (if any):

n/a

Aggregate nominal amount:

EUR Benchmark

Description:

Fixed rate 12yr due 3rd Jun 2038

Offer price:

TBC

Other offer terms:

Stabilisation:

Stabilising Manager(s):

HSBC Bank plc

Stabilisation period expected to start on:

27th May 2026

Stabilisation period expected to end no later than:

3rd July 2026

Existence, maximum size & conditions of use of over-allotment facility[1]:

5% of the aggregate nominal amount

Stabilisation Venue(s)

Over the counter (OTC)

 

In connection with the offer of the above securities, the Stabilisation Manager(s) may over-allot the securities or effect transactions with a view to supporting the market price of the securities at a level higher than that which might otherwise prevail. However, there is no assurance that the Stabilisation Manager(s) will take any stabilisation action and any stabilisation action, if begun, may be ended at any time. Any stabilisation action or over-allotment shall be conducted in accordance with all applicable laws and rules.

This announcement is for information purposes only and does not constitute an invitation or offer to underwrite, subscribe for or otherwise acquire or dispose of any securities of the Issuer in any jurisdiction.

 

In addition, if and to the extent that this announcement is communicated in, or the offer of the securities to which it relates is made in, any EEA Member State before the publication of a prospectus in relation to the securities which has been approved by the competent authority in that Member State in accordance with the Regulation (EU) 2017/1129 (the "Prospectus Regulation") (or which has been approved by a competent authority in another Member State and notified to the competent authority in that Member State in accordance with the Prospectus Regulation), this announcement and the offer are only addressed to and directed at persons in that Member State who are qualified investors within the meaning of the Prospectus Regulation (or who are other persons to whom the offer may lawfully be addressed) and must not be acted on or relied on by other persons in that Member State.

 

This announcement and the offer of the securities to which it relates are only addressed to and directed at persons outside the United Kingdom and persons in the United Kingdom who have professional experience in matters related to investments or who are high net worth persons within article 12(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 and must not be acted on or relied on by other persons in the United Kingdom.

 

This announcement is not an offer of securities for sale into the United States. The securities have not been, and will not be, registered under the United States Securities Act of 1933 and may not be offered or sold in the United States absent registration or an exemption from registration. There will be no public offer of securities in the United States.


[1] Please note that the existence and the maximum size of any greenshoe option, the exercise period of the greenshoe option and any conditions for exercise of the greenshoe option must also be disclosed, if such option exists. In addition, the exercise of the greenshoe option must be disclosed to the public promptly, together with all appropriate details, including in particular the date of exercise and the number and nature of securities involved 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
STAZZGZKRNRGVZG
Date   Source Headline
1st Mar 202212:11 pmRNSTotal Voting Rights
28th Feb 20226:06 pmRNSTransaction in Own Shares
25th Feb 20226:05 pmRNSTransaction in Own Shares
24th Feb 20226:11 pmRNSTransaction in Own Shares
23rd Feb 20226:18 pmRNSTransaction in Own Shares
23rd Feb 20229:00 amRNSDirector/PDMR Shareholding
22nd Feb 202212:30 pmRNSTransaction in Own Shares
22nd Feb 20227:01 amRNSSmith+Nephew announces new Chief Executive Officer
22nd Feb 20227:00 amRNSFinal Results
1st Feb 20224:30 pmRNSBlock listing Interim Review
1st Feb 20221:15 pmRNSTotal Voting Rights
25th Jan 202210:00 amRNSJo Hallas joins Smith+Nephew as NED
25th Jan 20229:00 amRNSNotice of Results
19th Jan 20225:00 pmRNSDirector/PDMR Shareholding
19th Jan 20227:00 amRNSS+N acquires novel cementless partial knee system
4th Jan 20221:12 pmRNSTotal Voting Rights
16th Dec 202112:00 pmRNSSmith+Nephew outlines ‘Strategy for Growth'
1st Dec 202112:08 pmRNSTotal Voting Rights
17th Nov 20212:00 pmRNSDirector/PDMR Shareholding
12th Nov 20214:30 pmRNSDirector/PDMR Shareholding
4th Nov 20217:00 amRNSTrading Statement
2nd Nov 202110:30 amRNSDirector/PDMR Shareholding
1st Nov 20213:00 pmRNSDirector/PDMR Shareholding
1st Nov 20211:53 pmRNSTotal Voting Rights
29th Oct 202111:45 amRNSDirector/PDMR Shareholding
22nd Oct 20219:00 amRNSSmith+Nephew to host Meet the Management event
15th Oct 20218:47 amRNSDividend Declaration
8th Oct 20219:00 amRNSNotice of Results
1st Oct 202110:16 amRNSTotal Voting Rights
24th Sep 20213:47 pmRNSDirector/PDMR Shareholding
17th Sep 20212:30 pmRNSAdditional Listing
16th Sep 20217:00 amRNSDirector/PDMR Shareholding
14th Sep 20215:00 pmRNSDirector/PDMR Shareholding
1st Sep 202110:59 amRNSTotal Voting Rights
27th Aug 20219:00 amRNSDirector/PDMR Shareholding
24th Aug 202110:30 amRNSDirector/PDMR Shareholding
23rd Aug 20211:00 pmRNSDirector/PDMR Shareholding
17th Aug 202111:15 amRNSDirector/PDMR Shareholding
4th Aug 202111:31 amRNSDirector/PDMR Shareholding
2nd Aug 20212:53 pmRNSBlock listing Interim Review
2nd Aug 202111:24 amRNSTotal Voting Rights
29th Jul 20217:00 amRNSHalf-year Report
19th Jul 20211:00 pmRNSDirector/PDMR Shareholding
7th Jul 20219:00 amRNSNotice of Results
1st Jul 202111:13 amRNSTotal Voting Rights
1st Jun 202111:48 amRNSTotal Voting Rights
25th May 20216:15 pmRNSDirector/PDMR Shareholding
21st May 20214:30 pmRNSDirector/PDMR Shareholding
18th May 20215:15 pmRNSDirector/PDMR Shareholding
14th May 20214:00 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.